fibroblast growth factor receptor 4 fgfr4 inhibitor pipeline insight

DelveInsight’s, "Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Understanding

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Overview

Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) support cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance and their deregulation is frequently observed in cancer development and progression. Consequently, increasing efforts are focusing on the development of strategies to target FGF/FGFR signaling for cancer therapy. Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) regulate important cellular processes such as cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance.

 

FGFR4 deletion does not lead to an embryonic lethal phenotype suggesting the possibility that its inhibition in cancer therapy might not cause grave adverse effects. The FGFR4 kinase domain differs sufficiently from those of FGFRs1-3 to permit development of highly specific inhibitors. The oncogenic impact of FGFR4, however, is not undisputed, as the FGFR4-mediated hormonal effects of several FGF ligands may also constitute a tissue-protective tumor suppressor activity especially in the liver.

 

"Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape is provided which includes the disease overview and Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The therapies under development are focused on novel approaches to treat/improve Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Emerging Drug Chapters

This segment of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Emerging Drugs

 

Pemigatinib: Incyte Corporation

Pemigatinib is an orally bioavailable, small molecule, and selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3 and 4. Pemigatinib is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

 

H3B-6527: H3 biomedicine

H3B-6527 is a selective, orally bioavailable, and covalent inhibitor of FGFR4 that has demonstrated tumor regression in several preclinical models of HCC. Receptor tyrosine kinases (RTKs) can be dysregulated in cancer cells and can frequently promote abnormally rapid tumor growth and development. Hepatocellular carcinoma (HCC) can be driven in this way by hyperactivation of the fibroblast growth factor receptor 4 (FGFR4). H3B-6527 is being tested specifically in patients with FGFR4-dysregulated advanced HCC.

Further product details are provided in the report……..

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist

There are approx. 15+ key companies which are developing the therapies Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

 

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Insights

• Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs?
• How many Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?